Skip to main content
Clinical Trials/NCT05742685
NCT05742685CompletedNot Applicable

Refinement and Adaption of Reinforcement Learning to Personalize Behavioral Messaging for Healthy Habits

Brigham and Women's Hospital1 site in 1 country28 target enrollmentStarted: August 23, 2023Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
28
Locations
1
Primary Endpoint
Diabetes medication adherence

Study Overview

Brief Summary

Reinforcement learning is an advanced analytic method that discovers each individual's pattern of responsiveness by observing their actions and then implements a personalized strategy to optimize individuals' behaviors using trial and error. The goal of the proposed research is to refine, adapt and perform efficacy testing of a novel reinforcement learning-based text messaging intervention to support medication adherence for patients with type 2 diabetes within a community health center setting. This study will be a parallel randomized pragmatic trial comparing medication adherence and clinical outcomes for adults in a community setting aged 18-84 with type 2 diabetes who are prescribed 1-3 daily oral medications for this disease. Participants will be randomized to one of two arms for the duration of the study period: (1) a reinforcement learning intervention arm with up to daily, tailored text messages based on time-varying treatment-response patterns; or (2) a control arm with up to daily, un-tailored text messages. Outcomes of interest will be medication adherence, as measured by electronic pill bottles, and HbA1c levels over 6 months.

Detailed Description

The goal of the proposed research is to refine, adapt and perform efficacy testing of a novel reinforcement learning-based text messaging intervention to support medication adherence for patients with type 2 diabetes within a community setting. Type 2 diabetes is an optimal condition in which to refine this program, as it is one of the most prevalent chronic conditions in the US adult population and requires most patients to be on daily or twice daily doses of medications. This study will be a parallel randomized pragmatic trial comparing medication adherence and clinical outcomes for adults in a community setting aged 18-84 with type 2 diabetes who are prescribed 1-3 daily oral medications for this disease. Participants will be randomized to one of two arms for the duration of the study period: (1) a reinforcement learning intervention arm with up to daily, tailored text messages based on time-varying treatment-response patterns; or (2) a control arm with up to daily, un-tailored text messages. Outcomes of interest will be medication adherence, as measured by electronic pill bottles, and HbA1c levels over 6 months.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Health Services Research
Masking
Double (Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to 84 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Diagnosis of Type 2 Diabetes Mellitus (T2DM)
  • •Prescribed between 1-3 daily oral medications for diabetes
  • •Most recent HbA1c level of 7% or greater
  • •Suboptimal adherence, defined by proportion of days covered (PDC) < 0.90 based on chart review
  • •Must have a smartphone for which they are the sole user
  • •Must have a basic working knowledge of English or Spanish

Exclusion Criteria

  • •Currently using a pillbox and/or not willing to use electronic pill bottles for 6 months
  • •Receive help at home on a daily basis with taking medications

Arms & Interventions

Reinforcement Learning Intervention Arm

Experimental

Up to daily, tailored text messages.

Intervention: Reinforcement Learning (Behavioral)

Control Arm

No Intervention

Up to daily, untailored text messages.

Outcomes

Primary Outcomes

Diabetes medication adherence

Time Frame: 6 months

Proportion of correct doses recorded by electronic pill bottles in the 6-month follow-up period, averaged across study medications

Secondary Outcomes

  • Glycemic control(6 months)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Julie Lauffenburger

Assistant Professor

Brigham and Women's Hospital

Study Sites (1)

Loading locations...

Similar Trials